ClinicalTrials.gov posted results on 11 September 2026 for a Phase 2 study of atezolizumab plus cabozantinib in patients with metastatic, refractory pancreatic cancer. The trial enrolled 32 participants, and the posted measurements included a disease control rate of 0.44 and overall response rate or stable disease values of 0.06 and 0.39.
The study was listed as active, not recruiting. Its intervention was cabozantinib combined with atezolizumab.
Background
The trial evaluated atezolizumab in combination with cabozantinib for metastatic pancreatic cancer that had become refractory to prior treatment. The registry described pancreatic cancer as having limited treatment options, particularly in metastatic disease. It also stated that the combination had demonstrated safety in other cancers and had shown promise in preclinical studies using patient-derived pancreas organoids.
Trial design
This Phase 2 study, identified as NCT04820179, enrolled 32 participants with pancreatic cancer or metastatic pancreatic cancer. Participants received cabozantinib plus atezolizumab. The registry described overall response rate as an efficacy measure, along with disease control and safety-related outcomes. No primary-outcome entries or comparator arm were listed in the supplied data.
Key results
For the group listed as cabozantinib 40 mg plus atezolizumab 1200 mg, the record reported two measurements for overall response rate or stable disease: 0.06 and 0.39 as proportions of participants. The record did not identify how these two values differed or provide confidence-interval values.
The reported disease control rate was 0.44 as a proportion of participants. The adverse-event outcome listed counts of 23 participants and 19 participants, while the toxicity outcome listed counts of 26 participants and 19 participants. The supplied record did not specify the categories or context represented by each paired count.
What this means
The posted results provide activity and safety-related measurements for atezolizumab plus cabozantinib in a small Phase 2 pancreatic cancer study. The 0.44 disease control rate and the two overall response rate or stable disease values describe the recorded outcomes, but the absence of primary-outcome entries, a comparator arm, confidence intervals, and explanations for the paired measurements limits interpretation. The adverse-event and toxicity counts also do not independently define the treatment’s safety profile because their categories were not supplied.
Source
Source: ClinicalTrials.gov, registry results for the Phase 2 study “Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer,” posted 11 September 2026. Available at clinicaltrials.gov/study/NCT04820179.